TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05744258

Intervention type: DEVICE
Group type: OTHER
Intervention: Bio-electrical impedance analysis
Description: Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated.

Intervention type: DEVICE
Group type: OTHER
Intervention: Bio-electrical impedance analysis
Description: Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated.
Study: NCT05421221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sniffin' sticks Duftquartett
Description: 4-odor training set over 12 weeks with Sniffin' sticks Duftquartett
Study: NCT04870827

Intervention type: DRUG
Intervention: 13N Amonia
Description: Administered during PET/CT scans
Study: NCT05046392

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face ART Adherence Intervention
Description: All participants will receive a one hour face-to-face session with an adherence coach, based on LifeSteps. The session will cover behavioral skills that are important for maintaining adherence to ART and will explore potential barriers for managing each skill. Cognitive-behavioral therapy, problem solving, and motivational interviewing techniques are used to explore barriers and create health goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face ART Adherence Intervention
Description: All participants will receive a one hour face-to-face session with an adherence coach, based on LifeSteps. The session will cover behavioral skills that are important for maintaining adherence to ART and will explore potential barriers for managing each skill. Cognitive-behavioral therapy, problem solving, and motivational interviewing techniques are used to explore barriers and create health goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carium Mobile Health Platform
Description: Participants assigned to the experimental condition will receive access to a mobile health app, called Carium, for 12 months. The app will be used to facilitate continued coaching from the adherence coach. The app incorporates automated medications reminders with interactive adherence coaching via a secure messaging feature. Participants will receive custom medication reminders as push notifications that will ask them to indicate if they have taken their medication or not. This will allow adherence coaches to monitor self-reported adherence in the app. Adherence coaches will use the secure messaging feature to check-in with participants and reach out to participants who appear to be struggling with adherence and offer assistance.
Study: NCT04945486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-mentor intervention
Description: Peer-mentor support for up to 6 months
Study: NCT05120050

Intervention type: DEVICE
Intervention: ASP Health instrument
Description: The instrument is an integrated device with a short processing time (measured in 2 to 3 minutes) that distributes cells from limited volume samples (measured in microliters). The process involves a novel aerosolization technique that transfers liquid sample to a glass slide via a burst of air. After the sample is deposited on the glass slide, the automated system uses an integrated heating strip to heat the specimen slide. This process is similar to using a hair dryer to dry the specimen slide in the current ROSE setting. After drying the slide, the system uses series of pumps to dispense microliters of stain reagent onto the slide to stain the cells. Currently, the system is configured to perform DiffQuik staining, which is commonly used in the ROSE process. In the future, the staining capability will be broadened to include other staining processes such as Rapid PAP, H\&E staining etc.
Study: NCT05344625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 100 MG/ML
Description: Ketamine Assisted Psychotherapy
Study: NCT05052541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Oral solution containing 5mg THC per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Oral solution containing 5mg THC per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Oral solution containing 5mg THC per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Oral solution containing 5mg THC per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Oral solution containing 5mg THC per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Oral solution containing 5mg THC per 1 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution containing no active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution containing no active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution containing no active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution containing no active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution containing no active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution containing no active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution containing no active drug
Study: NCT06041646

Intervention type: DRUG
Group type: OTHER
Intervention: Sublingual film containing Igalmi
Description: Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
Study: NCT04828785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTM
Description: weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Subsidy
Description: $40/month food subsidy
Study: NCT05516693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial muscle training protocol.
Description: Muscle training for orofacial motricity stimulation
Study: NCT05960110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: Fluoride varnish 26200 ppm

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fluoride toothpaste
Description: Fluoride toothpaste 1450 ppm
Study: NCT03038802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic hepatitis B vaccine
Description: HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
Study: NCT05960357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To inform
Description: It includes providing all necessary information about the fetus to the pregnant woman by using the ultrasound monitor during the detailed ultrasound.
Study: NCT05515328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C] BI 685509 formulation 1
Description: \[¹⁴C\] BI 685509 formulation 1
Study: NCT03038802

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Hepatitis B vaccine
Description: Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
Study: NCT05515328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C] BI 685509 formulation 2
Description: \[¹⁴C\] BI 685509 formulation 2
Study: NCT05977153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP (positive end-expiratory pressure) - maximum
Description: Breathing assistance from the breathing assist machine using a method in which doctors try to find the pressures that expands the lungs the best. This is based on measurements of one's respiratory pressures and volumes. This is done by adjusting the pressure settings. This allows one's lungs to expand with the least amount of change in pressure during breathing.~PEEP (positive end-expiratory pressure) will be set at the maximum static respiratory system compliance (Crs) during a descending PEEP titration curve.
Study: NCT05515328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509 formulation 3
Description: BI 685509 formulation 3
Study: NCT05977153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP (positive end-expiratory pressure) - standard
Description: Breathing assistance from the breathing assist machine using the pressure settings typical for your disease.~Standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol: PEEP will be set following a routinely used PEEP table according to patients' blood oxygenation status.
Study: NCT05331456

Intervention type: DEVICE
Group type: OTHER
Intervention: Unilateral alveolar cleft repair
Description: Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty

Intervention type: DEVICE
Group type: OTHER
Intervention: Unilateral alveolar cleft repair
Description: Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty
Study: NCT06396572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVR-Procedure
Description: Using immersive virtual reality to learn urinary catheterisation procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nursing Clinical Laboratory practice
Description: Using nursing clinical laboratory sessions to learn urinary catheterisation procedure
Study: NCT06152419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information.
Study: NCT04715256

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive assessment of obsessive-compulsive and impulsive behaviours
Description: The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
Study: NCT04842500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demand Informed Moderator Analysis
Description: This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demand Informed Moderator Analysis
Description: This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demand Informed Moderator Analysis
Description: This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demand Informed Moderator Analysis
Description: This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).
Study: NCT05335993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: 2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.
Study: NCT04795908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention
Description: Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
Study: NCT05077436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 1
Description: Vamifeport Formulation 1 is available as 60 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 1
Description: Vamifeport Formulation 1 is available as 60 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 1
Description: Vamifeport Formulation 1 is available as 60 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 1
Description: Vamifeport Formulation 1 is available as 60 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 2
Description: Vamifeport Formulation 2 is available as 60 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 2
Description: Vamifeport Formulation 2 is available as 60 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 2
Description: Vamifeport Formulation 2 is available as 60 mg oral capsules
Study: NCT04715256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment of obsessive-compulsive and impulsive behaviours
Description: The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: Genomic analysis
Description: A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
Study: NCT04970446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: All patients will receive a one week course of antibiotic therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotics
Description: All patients will receive a one week course of antibiotic therapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietician designed diet
Description: All patients will be recommended dietary modification 3 weeks prior to, and during, the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietician designed diet
Description: All patients will be recommended dietary modification 3 weeks prior to, and during, the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMT
Description: Anaerobically prepared stool. Dosing will vary according to mode of administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will contain food colourant, 0.9% normal saline and glycerol.
Study: NCT06217692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: nutrition education
Study: NCT04715256

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic analysis
Description: A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Glucoregulation assessment
Description: Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucoregulation assessment
Description: Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
Study: NCT04961918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
Description: Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
Study: NCT05474807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered strengths use intervention
Description: The online strengths use intervention program, will be based on Miglianico et al.'s (2020) general framework, following the theorized five stages: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation.~As to increase participant engagement and motivation, gamification components will be embedded in several of these stages.~The entire intervention will be delivered online via an LMS software solution.
Study: NCT06015412

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic classification
Description: disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic classification
Description: disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic classification
Description: disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic classification
Description: disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
Study: NCT04658472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (IV)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (IV)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (IV)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (IV)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (IV)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (SC)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (SC)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (SC)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (SC)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (SC)
Description: Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
Study: NCT06553846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium [177Lu]-FAP-75
Description: Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
Study: NCT06330285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning
Description: CPET (Cardiopulmonary exercise test) e-learning application The content, planning and design of 4 lessons are as follows:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: face to face learning
Description: CPET (Cardiopulmonary exercise test) face to face education. The content, planning and design of 4 lessons are as follows:~Contents:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples
Study: NCT05519618

Intervention type: PROCEDURE
Intervention: Epidural veins pressure and flow measurement
Description: The purpose of this study is to measure to pressure and flow of epidural venous plexus.~The procedure will be performed alongside during pre-operative embolization at the angiography suite.~It will be performed under general anesthesia. A the start of the procedure, a venous access will be established at the inguinal region. Co-axial catheters will be navigated to epidural venous plexus under the guidance of fluoroscopy. After the placement of catheter, the pressure and flow of epidural venous plexus will be measured at three time points: 1. Right after catheter reach the targeted location 2. Right before embolization. 3. After embolization. The participant will be instructed to control their breathe during measurement.~After measurement, the catheter will be removed alongside with embolization devices, and achieved hemostasis as routine.